Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Clinical trial NCT02811861 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02811861
- Sponsor
- Eisai Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-13
- Primary completion
- 2020-08-28
- Enrollment
- 1069
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.